QUESTIONS| Event Date/Time: Apr 25, 2012 | End Date/Time: Apr 26, 2012 |
Report as SpamDescription
Diabetes still remains an incurable disease which is affecting an increasing number of people in the world. This provides an expanding and resilient market for pharmaceutical management of the disease. The US market alone is expected to grow from $56.7Bn to $73.6Bn from 2015 to 20211. Diabetes is now a global disease due to an increasingly aging and sedentary population, with strong growth expected in emerging markets that will drive near term growth in diagnostics and uptake of pharmaceuticals.
Diabetic retinopathy is the leading cause of blindness in working age people2. It affects 80% of patients who have had diabetes for 10 years or longer and results in a huge financial burden3. This conference will look at the latest advances in this field and the results of key clinical trials.
Visiongain's 6th Annual Diabetes Conference will provide a unique networking event to boost your understanding of:
- Combating microvascular damage caused by hyperglycaemia using new drugs and management techniques
- Targeting the build up of cholesterol and lipid in the arteries which are exacerbated in diabetes due to dislipidaemia
- Challenges for development of new drugs such as study design, clinical trial regulations and approval of drugs
- Market trends for the future of the diabetic market, including looking at disease epidemiology and methods to penetrate developing markets
- Development of monocolonal antibody treatments to target proliferative retinopathy
- Advances in next generation glucose monitoring equipment that is less invasive to help increase patient compliance with regular testing
- The implications of inflammation in the body as a result of diabetes and its effects on vascular disease
- Using GLP-1 analogues to treat obesity and diabetes
- Regulatory updates in diabetic care from the MHRA
- Results of key clinical trials (EUCLID, RASS, ASPEN, FIELD)
Diabetic retinopathy is the leading cause of blindness in working age people2. It affects 80% of patients who have had diabetes for 10 years or longer and results in a huge financial burden3. This conference will look at the latest advances in this field and the results of key clinical trials.
Visiongain's 6th Annual Diabetes Conference will provide a unique networking event to boost your understanding of:
- Combating microvascular damage caused by hyperglycaemia using new drugs and management techniques
- Targeting the build up of cholesterol and lipid in the arteries which are exacerbated in diabetes due to dislipidaemia
- Challenges for development of new drugs such as study design, clinical trial regulations and approval of drugs
- Market trends for the future of the diabetic market, including looking at disease epidemiology and methods to penetrate developing markets
- Development of monocolonal antibody treatments to target proliferative retinopathy
- Advances in next generation glucose monitoring equipment that is less invasive to help increase patient compliance with regular testing
- The implications of inflammation in the body as a result of diabetes and its effects on vascular disease
- Using GLP-1 analogues to treat obesity and diabetes
- Regulatory updates in diabetic care from the MHRA
- Results of key clinical trials (EUCLID, RASS, ASPEN, FIELD)
Venue
Additional Information
Key Speakers
- MHRA
- Eli Lilly
- Boehringer Ingelheim
- F. Hoffmann-La Roche
- Harvard University
- Madrigal Pharmaceuticals
- Imagepace, Imaging Core Lab of Medpace
- Exsulin Corporation
- German Diabetes Centre
- UCL
- Moorfields Eye Hospital
- Imperial College
- Imperial College
- Enterome
